Cryptococcal Meningitis

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Cryptococcal Meningitis trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 4 trials

RecruitingNot Applicable

NCT00867269

Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

Background: * Idiopathic CD4+ lymphocytopenia (ICL) is a condition in which there is a decreased level of CD4+ lymphocytes (a type of white blood cell), which…

United States950 participantsStarted 2009-07-13

RecruitingPhase 2/3

NCT03945448

Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia

This will be a randomized controlled trial of asymptomatic (Cryptococcal Antigen test)CrAg positive persons in Uganda. Patients will be randomized to receive p…

Uganda356 participantsStarted 2019-06-20

Treatment: Single dose liposomal Amphotericin and Fluconazole, Fluconazole

RecruitingNot Applicable

NCT00001352

Fungal Infection Susceptibility

The protocol will be carried out in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Go…

United States800 participantsStarted 1993-04-01

RecruitingPhase 2/3

NCT06666322

Platform Trial For Cryptococcal Meningitis

Cryptococcal meningitis is a fungal infection that causes a severe syndrome of meningitis that is 100% fatal without antifungal therapy. Even with antifungal th…

Uganda2,000 participantsStarted 2025-05-28

Treatment: Standard of care, Oteseconazole - antifungal therapy 1

All recent trials (53 shown)

CompletedPhase 2

NCT06414512

Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis

Cryptococcal meningitis (CM) is a fungal infection that causes a severe syndrome of meningitis that is 100% fatal without antifungal therapy. Even with antifung…

Uganda48 participantsStarted 2024-04-09

Treatment: AMBITION trial control, Flucytosine

By InvitationPhase 4

NCT06178627

Amphotericin B for Non-HIV Cryptococcal Meningitis Patients

Cryptococcus neoformans and C. gatti are important causes of central nervous system (CNS) infections with significant mortality, remaining a great public health…

China250 participantsStarted 2023-08-13

Treatment: Amphotericin B 0.5 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks., Amphotericin B 0.7 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.

Cryptococcal Meningitis

Trial phase breakdown

Trial status

Actively recruiting — 4 trials

Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia

Fungal Infection Susceptibility

Platform Trial For Cryptococcal Meningitis

All recent trials (53 shown)

Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis

Amphotericin B for Non-HIV Cryptococcal Meningitis Patients

Trial phase breakdown

Trial status

Actively recruiting — 4 trials

Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia

Fungal Infection Susceptibility

Platform Trial For Cryptococcal Meningitis

All recent trials (53 shown)

Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis

Amphotericin B for Non-HIV Cryptococcal Meningitis Patients

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)

Point of Care Tests to Identify Opportunistic Infections in Advanced HIV Patients in Mexico City

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3

Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis

Driving Reduced AIDS-associated Meningo-encephalitis Mortality

Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis

The Lived Experience of Participants in an African Randomised Trial

High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals

A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Compa…

Dexamethasone in Cryptococcal Meningitis

Three Induction Treatments on Cryptococcal Meningitis

Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis

Cryptococcal Optimal ART Timing Trial

Operational Research for Cryptococcal Antigen Screening

Treatment With Tamoxifen in Cryptococcal Meningitis

AmB Dose for Cryptococcal Meningitis

CryptoART Study: Decreasing Mortality Associated With Initiation of Antiretroviral Therapy in Sub-Saharan Africa

Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report